Clinical Scorecard: Geographic Atrophy: Fact or Fiction

At a Glance

Key Highlights

• GA does not cause total blindness but can lead to significant central vision loss.
• All forms of AMD are detrimental; there is no 'good' AMD.
• GA progression is generally faster than previously believed, averaging 2.5 years from diagnosis to central vision loss.
• Recent FDA approvals for GA treatments (pegcetacoplan and avacincaptad pegol) can slow progression.
• Regular monitoring and comprehensive care are essential for managing GA.

Guideline-Based Recommendations

Diagnosis

• Assess visual function and clarity in patients with AMD.
• Monitor for signs of GA progression.

Management

• Consider FDA-approved treatments for GA.
• Encourage lifestyle modifications such as smoking cessation and a diet rich in leafy greens and omega-3 fatty acids.

Monitoring & Follow-up

• Regular follow-ups with eye care specialists are crucial.
• Evaluate the impact of GA on daily living activities.

Risks

• Patients may experience severe visual impairments without appropriate referrals to low vision specialists.
• Comorbidities like glaucoma and dry eye can exacerbate visual impairment.

Patient & Prescribing Data

Individuals diagnosed with GA as part of AMD.

Emerging therapies can slow GA progression, but comprehensive care is necessary for optimal outcomes.

Clinical Best Practices

• Educate patients about the nature of GA and its implications for vision.
• Facilitate referrals to low vision specialists when necessary.
• Incorporate discussions about visual aids and optical corrections into patient care.

References

• Geographic Atrophy Overview